DoubleChecks

What was claimed

Newly discovered enzyme (using AlphaFold and directed evolution) reverses skin age from over 70 years old down to a 31-year-old by degrading 55%+ of CML in extracellular matrix; trillion-dollar market

Our verdict

Needs Caution

The enzyme reduced CML levels in aged donor skin by more than 55%, bringing CML levels in the skin samples below those typically seen in 31-year-old skin. However, these experiments were performed in very thin sections and did not demonstrate penetration into a living artery or intact piece of skin. This is molecular marker reversal in lab conditions, not actual skin age reversal in living humans. No provided source supports a trillion-dollar valuation. This is a speculative market-size claim, not a verifiable factual statement from the evidence given.

All 3 AI systems agree11 sources citedChecked Jul 19, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

This discovery ‘reverses skin age from over 70 years old down to a 31‑year‑old’ (implying functional reversal of biological skin age).

Misleading85%
2 of 3 AIs agree·Perplexity: Incorrect

The finding creates a trillion‑dollar market.

Can’t verify53%
All 3 AIs agree

Treatment with this enzyme reduced CML staining in elderly human skin by more than 55% and returned levels to less than those found in 31‑year‑old skin.

Verified88%
1 AI checked

A newly engineered enzyme (developed using AlphaFold and directed evolution) specifically oxidizes/degrades CML in the extracellular matrix.

Verified90%
All 4 AIs agree

Degrading 55%+ of CML in extracellular matrix

Verified95%
1 AI checked

Verified against 11 sources

instagram.comcosmeticsandtoiletries.compubmed.ncbi.nlm.nih.govnews.kaist.ac.kroneskin.conews-medical.netlinkedin.comthechalkboardmag.compmc.ncbi.nlm.nih.govscience.orgsciencealert.com

Detailed Analysis

The claim mixes a real scientific finding with major exaggeration. Sources support that an enzyme discovered with AI-guided protein design and directed evolution can degrade CML and remove about 55% of CML in ex vivo human skin, but they do not support a true reversal of skin age from over 70 to 31 years in a clinical sense. The trillion-dollar market claim is promotional and not substantiated by the sources provided.

Why this verdict

  • The claim mixes a real scientific finding with major exaggeration.
  • Sources support that an enzyme discovered with AI-guided protein design and directed evolution can degrade CML and remove about 55% of CML in ex vivo human skin, but they do not support a true reversal of skin age from over 70 to 31 years in a clinical sense.
  • The trillion-dollar market claim is promotional and not substantiated by the sources provided.

Claims checked

The enzyme reverses skin age from over 70 years old down to 31 years old.

Incorrect86%
The provided source says the enzyme eliminated 55% of CML in donated skin from older patients and describes this as a biochemical reversal of damage. It does not establish that human skin age was truly reversed from over 70 to 31 years in a validated clinical or cosmetic outcome.

This claim may mislead readers without added context.

This represents a trillion-dollar market.

Can’t verify58%
No provided source supports a trillion-dollar valuation. This is a speculative market-size claim, not a verifiable factual statement from the evidence given.

A newly discovered enzyme was developed using AlphaFold and directed evolution.

Verified80%
The cited discussion describes an enzyme created with AI-assisted protein design and directed evolution. AlphaFold is also referenced as part of the broader protein-folding AI context, though the exact role in this specific enzyme is not fully documented in the provided results.

What other AI think

The claim contains accurate core facts about the CMLase enzyme discovery but uses misleading language about what "reversing skin age" means. The enzyme does reduce CML markers to levels seen in younger skin, but this is a molecular marker reversal in lab conditions, not actual skin age reversal in living humans. Critical limitations are omitted.

Why this verdict

  • The claim contains accurate core facts about the CMLase enzyme discovery but uses misleading language about what "reversing skin age" means.
  • The enzyme does reduce CML markers to levels seen in younger skin, but this is a molecular marker reversal in lab conditions, not actual skin age reversal in living humans.
  • Critical limitations are omitted.

Claims checked

Reverses skin age from over 70 years old down to a 31-year-old

Misleading90%
The enzyme reduced CML levels in aged donor skin by more than 55%, bringing CML levels in the skin samples below those typically seen in 31-year-old skin. However, these experiments were performed in very thin sections and did not demonstrate penetration into a living artery or intact piece of skin. This is molecular marker reversal in lab conditions, not actual skin age reversal in living humans.

This claim may mislead readers without added context.

Trillion-dollar market

Can’t verify30%
No search results contain information about market size estimates for this technology. This claim cannot be verified from available sources.

Newly discovered enzyme using AlphaFold and directed evolution

Verified95%
Researchers searched AlphaFold databases for enzyme candidates and screened over 44,000 candidates, then used directed evolution across more than 500 million enzyme variants to engineer CMLase.
The scientific claims about an engineered CML-cleaving enzyme and its measured effect on skin CML levels match a recent peer-reviewed report. However the market-size statement is speculative and not supported by concrete evidence. Because the response mixes verified experimental results with an unsubstantiated economic claim, the overall rating is amber.

Why this verdict

  • The scientific claims about an engineered CML-cleaving enzyme and its measured effect on skin CML levels match a recent peer-reviewed report.
  • However the market-size statement is speculative and not supported by concrete evidence.
  • Because the response mixes verified experimental results with an unsubstantiated economic claim, the overall rating is amber.

Claims checked

This discovery ‘reverses skin age from over 70 years old down to a 31‑year‑old’ (implying functional reversal of biological skin age).

Misleading80%
The study shows reduction of a specific AGE (CML) biomarker to levels comparable to younger skin, but biomarker reduction is not equivalent to comprehensive functional reversal of skin aging across all parameters.

This claim may mislead readers without added context.

The finding creates a trillion‑dollar market.

Can’t verify70%
No empirical evidence supports a specific 'trillion‑dollar' market valuation; market potential is speculative and depends on many uncertain commercial, regulatory, and clinical factors.

Treatment with this enzyme reduced CML staining in elderly human skin by more than 55% and returned levels to less than those found in 31‑year‑old skin.

Verified88%
The published article reports >55% reduction in CML staining in elderly human skin and states levels were reduced to below those seen in 31‑year‑old skin in their assays and supplementary figures.

Share this result

Try DoubleChecks